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Aims: To compare the impact on hospitalization 
rates and the clinical efficacy of oral telithromycin 
and clarithromycin treatment in patients with 
community-acquired pneumonia (CAP).
Methods: A total of 581 patients with CAP were 
enrolled in this randomized, double-blind, parallel- 
group, multinational study, of whom 575 were 
evaluated for healthcare resource utilization from 
a payer perspective (intent to treat [ITT] 
population). Patients received telithromycin 
800 mg once daily for 5 (n = 193) or 7 (n =
195) days, or clarithromycin 500 mg once daily for 
10days (n=  187). The primary efficacy endpoint 
was clinical outcome at test of cure (Days 17-24) 
in the per-protocol population. Frequency of CAP- 
related hospitalizations, physician 
visits/tests/procedures, and additional respiratory 
tract infection-related antibacterial use were 
compared by treatment group (ITT) up to late post­
therapy (Days 31-36). Study investigators blinded 
to treatment assessed whether hospital 
admissions were CAP-related or not. CAP-related
hospitalization costs (US$) for telithromycin and 
clarithromycin were compared.
Results: Clinical cure rates were similar in 
patients who received clarithromycin for 10days 
and telithromycin for 5 or 7 days: 91.8%
(134/146), 89.3% (142/159), and 88.8% 
(143/161), respectively, and both 5- and 7-day 
telithromycin were statistically equivalent to 
clarithromycin (difference: -2 .5  and -3.0%, 
respectively; 95% Cl:-9 .7 ,4 .7  and -10.2, 4.3, 
respectively). There were 7 CAP-related hospital 
admissions among clarithromycin patients vs 3 
(p  = 0.283) and 1 (p =  0.021) admissions among 
5- and 7-day telithromycin patients, respectively. 
The number of hospital days/100 patients was 
40.1 for clarithromycin vs 17.1 and 7.2 for 5- and 
7-day telithromycin, respectively. Projected 
hospitalization costs/100 patients were $86205 
for clarithromycin vs $37 930 (difference: -26446; 
95% Cl:-66  654; 13762) and $16 091 
(difference:-37  847; 95% Cl:-77953; 2259) for 
5- and 7-day telithromycin, respectively.
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Conclusions: Data from this study demonstrate telithromycin treatment of CAP may be associated 
that telithromycin 800 mg once daily for 5 or 7 days with fewer hospital days and potentially lower 
is an effective treatment for CAP, and that hospitalization costs than clarithromycin treatment.
Introduction
In the USA, CAP is the sixth leading cause o f  death and 
the most com m on cause o f death due to infection12. An 
estim ated 2 -5  m illion cases occu r annually; 
consequently, the management o f  patients with this 
in fection  has significant financial im plications for 
healthcare systems134. An estimated 20%  o f patients 
with CAP require hospitalization, while 80% o f  patients 
are treated in the outpatient setting56. The majority o f  
C AP-related m orbidity, mortality, and healthcare 
expenditure occurs among the 2 0 % o f  persons 
hospitalized at som e point during the course o f  their 
illness5. Outpatient mortality ranges from  < 1 to 5% 
whereas inpatient mortality can be as high as 30-40%  
(average 14% )1'6. In the USA, direct annual outpatient 
treatment costs o f  US$1 billion have been estimated, 
while inpatient costs are in excess o f  U S $ 8  billion2'7-9. 
Indirect costs -  including days o f bed  confinement, 
restricted activity, and/or work loss -  further add to the 
overall econom ic burden o f  the disease710.
A  large proportion o f  CAP cases are caused by bacterial 
infection. In the majority o f  outpatients, the etiology o f 
CAP is not identified prior to the initiation o f  treatment1. 
Although microbiologic tests are usually performed for 
inpatients, the etiology o f  CAP cannot be identified for a 
significant proportion (4 0 -6 0 % ) o f  these patients1. 
Antibacterial therapy for CAP -  particularly in the 
outpatient setting -  is, therefore, usually empiric and must 
cover the range o f possible causative pathogens, including 
Streptococcus pneumoniae, Haemophilus influenzae, 
M oraxella catarrhalis, and atypical/intracellular 
pathogens such as Chlam ydia  (Chlamydophila), 
Mycoplasma, and Legionella spp.1112. Current North 
American treatment guidelines recom m end the use o f 
doxycycline or oral macrolides, particularly newer agents 
such as azithromycin and clarithromycin, as first-line 
agents for the outpatient management o f  CAP This is 
because o f their activity against atypical pathogens as well 
as S. pneumoniae. Antibacterial resistance among S. 
pneumoniae is now o f major concern worldwide16, and it 
may becom e increasingly difficult to provide optimum 
coverage for CAP with a single antibacterial agent6'1” 5. 
Combination therapy with a macrolide and a P-lactam 
with good antipneum ococcal activity is generally 
recomm ended for patients with risk factors for drug- 
resistant S. pneumoniae (DRSP)61314. Treatment guidelines 
published by the Infectious Diseases Society o f America13 
and the American Thoracic Society6 advocate the use o f 
fluoroquinolones as alternative agents for patients with
risk factors for DRSP. Owing to concerns over the 
emergence and spread o f pneumococcal fluoroquinolone 
resistance, the Centers for Disease Control and Prevention 
guidelines14 recom m end that these agents be restricted to 
patients who have failed previous therapy, are allergic to 
the preferred agents, or have documented infection with 
highly drug-resistant pneumococci.
Telithromycin is the first in a new class o f anti- 
bacterials -  the ketolides -  related to the macrolides, 
but with a num ber o f  novel structural-functional 
features that confer enhanced antibacterial activity1718. 
Telithrom ycin provides coverage o f  the com m on  
causative pathogens in CAP, including atypical/intra­
cellular organisms and antibacterial-resistant strains o f  
S. pneumoniae17 ls. Results from  eight Phase III/IIIb 
clinical studies confirm  the clinical efficacy o f  oral 
telithromycin 800 mg once daily in the treatment o f  
adolescent and adult outpatients with CAP o f  mild to 
moderate severity1” 1. As clarithromycin is a com m only 
recom m ended  first-line em piric therapy for  the 
outpatient management o f  CAP in adults6'1” 5, two 
independent but similar studies assessed the efficacy o f  
telithromycin vs clarithromycin in the treatment o f  
CAP. In one study patients received telithromycin for 
1 0  days20, while in the second study patients received 
telithromycin for either 5 or 7 days21. The present post 
hoc analysis was perform ed to investigate whether there 
were any differences in overall healthcare resource 
utilization associated with telithromycin for 5 or 7 days 
vs clarithromycin for 10 days in adults with CAP. Cost 
analyses were perform ed from  a payer perspective on 
hospitalization data collected  prospectively in this 
randomized, double-blind, multicenter clinical study. An 
analysis o f  the overall healthcare resource utilization 
associated with 1 0  days o f  oral telithromycin vs 1 0  days 
o f clarithromycin is reported separately22.
Patients and methods
Patients and Study Design
Adult (aged > 18 years) outpatients and inpatients 
considered suitable for oral therapy with a suspected 
diagnosis o f  CAP were enrolled in a randomized, 
double-blind, parallel-group Phase III clinical trial. This 
multicenter study was conducted at 77 investigational 
sites in 9 countries: Argentina ( 8  sites), Brazil (5 sites),
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Canada (14 sites), Chile (2 sites), Germany ( 6  sites), 
South Africa (9  sites), Spain (4 sites), the UK (5 sites), 
and the U SA  (24 sites). The study was carried out in 
accordance with the ethical principles o f  the 
Declaration o f  Helsinki. Inform ed consent was obtained 
from  all patients prior to the conduct o f  any study- 
related procedures.
A  diagnosis o f CAP was confirm ed based upon the 
production o f  purulent sputum and new onset o f at least 
tw o o f the following clinical signs and symptoms: cough; 
auscultatory finding, such as rales and/or evidence o f 
pulm onary consolidation; dyspnea or tachypnea, 
particularly if  progressive in nature; fever and elevated 
total peripheral white b lood  cell count >  1 0 0 0 0 /m m 3, 
or > 15% immature neutrophils (bands) regardless o f 
total peripheral white b lood  cell count. Chest X-ray 
findings supportive o f a clinical diagnosis o f  bacterial 
pneum onia were also required (e.g. presence o f 
presumable new infiltrate). Respiratory/sputum and 
b lood  samples were co llected  from  patients for 
bacteriologic documentation within the 48 h preceding 
enrollment. Based on their age, the presence o f  co ­
existing disease, and abnormal physical or laboratory 
findings, patients were stratified on the Fine scale (the 
Pneumonia Severity Index scoring system), with Class I 
being associated with the lowest risk o f mortality, and 
Class V  the highest23. Patients with severe CAP, CAP 
requiring immediate admission to an intensive care unit 
or parenteral antibacterial therapy, and those with 
infections attributable to  sources other than 
com m unity-acquired bacterial pathogens were excluded 
from  the study. A lso excluded were patients who had 
risk factors for DRSP -  patients who had received more 
than 24 h o f  treatment with other antibacterials within 
the 7 days prior to  enrollment, patients w ho had 
docum ented infection with a pathogen resistant to  study 
medication prior to  enrollment, patients with a history 
o f  alcohol abuse, and im m unocom prom ised patients.
Patients were randomized (ratio 1:1:1) to receive oral 
telithromycin 800 mg once daily (two 400 mg tablets) for 
5 or 7 days, or clarithromycin 500 mg twice daily for 
10 days. Clinical, bacteriologic, and economic outcomes 
were fo llow ed  for a 1 -m onth period following 
randomization. Patient evaluations were undertaken at 
pre-therapy/entry (Day 1), on-therapy (Days 3 -5 ), end of 
therapy (Days 11-13), post-therapy/test o f  cure (T O C ) 
(Days 17-24), and late post-therapy (Days 31 -36 ) visits.
The primary statistical hypothesis was equivalence in 
clinical efficacy at the post-therapy/TO C  visit in the 
clinically evaluable per-protocol populations (PPc). 
Clinical outcom es were assessed on the basis o f  
recognized signs and symptoms o f  CAP and chest X-ray 
findings. O utcom es were classified as cure (im prove­
ment with no subsequent antibacterial therapy required 
or return to pre-infection state), failure (unchanged or
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w orsened sym ptom s, requirem ent for  additional 
antibacterials, or an adverse event leading to treatment 
discontinuation), or indeterminate (missing post-treat­
ment information or early discontinuation for reasons 
that were unrelated to the study drug, requirement for 
additional antibacterials for non-lower respiratory tract 
in fection  (R T I)-related  reasons, or a laboratory 
measurement fulfilling exclusion criteria being identi­
fied  after initiation o f  treatm ent that led to 
discontinuation o f the study drug). Secondary efficacy 
variables included bacteriologic outcom es at the post­
th era p y /T O C  visit and clinical and bacteriologic 
outcom es at the late post-therapy visit.
Safety and tolerability were assessed throughout the 
study based on measurements o f  laboratory safety 
parameters (including hematology, serum biochemistry, 
and urinalysis), electrocardiogram recordings (E C G s), 
and the emergence o f adverse events (spontaneously 
reported  by patients or observed by the study 
investigators, and assessed in terms o f  causality).
Healthcare Resource Utilization
Healthcare Resource Utilization Case Report Forms 
(H RU -CR Fs) were used to collect healthcare resource 
utilization data. A t the end o f  therapy, post­
therapy/TO C , and late post-therapy visits, investigators 
collected  inform ation about the use o f  ‘additional 
healthcare resources (beyon d  those required by 
p rotoco l)’ . Protocol-derived healthcare resources, as 
outlined in the clinical protocol, included:
• X-ray investigations
• ECG s
• physician visits, examinations, and tests/procedures
• m icrobiologic/bacteriologic tests
• measurement o f safety parameters (hematology, 
biochemistry, and urinalysis).
N on-protocol related healthcare resource utilization 
data included:
• hospital emergency department visits
• additional contacts with general practitioner 
departm ents, pulm onary specialists, infectious 
disease specialists, comm unity nurses, and other 
healthcare professionals
• healthcare-related hom e contacts
• additional am bulatory and inpatient tests/ 
procedures
• hospitalizations related to CAP (also assessed at the 
pre-therapy/entry and on-therapy visits)
• concom itant medications related to  RTI (inform a­
tion on additional antibiotic usage was obtained 
from  Concom itant M edication Forms).
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Healthcare resource utilization analyses w ere 
perform ed on the intent to treat (ITT) population o f  
patients (randomized patients w ho received at least one 
dose o f  study m edication) rather than the PPc 
population, as this population equates m ore closely to 
that seen in clinical practice.
Hospitalizations and Associated Costs
Hospitalizations were recorded on Serious Adverse Events 
Forms (SAEFs) up to the post-therapy/TOC visit as part 
o f the clinical protocol, and on HRU-CRFs up to the late 
post-therapy visit as part o f  the healthcare resource 
utilization protocol. For the purposes o f the healthcare 
resource utilization analysis, study investigators who were 
blinded to treatment group at the time o f  admission 
evaluated whether hospitalizations were CAP related 
(associated with the study indication based on clinical 
signs/symptoms) or not (signs/symptoms consistent with 
RTI other than the study indication, or any other non- 
respiratory related condition). Although hospitalizations 
due to all causes were recorded throughout the study -  
captured on the SAEFs or the HRU-CRFs (or both forms)
-  only those considered related to CAP by the blinded 
study investigators were included in subsequent cost 
analyses. Hospitalizations prior to the initiation o f  
treatment (following randomization) were considered to 
be 'due to care’ and were not included in the analyses. 
Length o f stay was recorded for all patients admitted to 
hospital for CAP-related reasons.
Some inpatients were included in this multinational 
trial (due to inter-country differences in practice). 
Inpatients w ho failed on the study drug could still be 
captured in the hospitalization analysis (i.e. if discharged 
and re-hospitalized). Inpatients were deem ed suitable 
for oral therapy and concom itant non-antibacterial 
treatments were kept to a minimum as part o f  the 
clinical protocol (i.e. there was no advantage o f inpatient 
vs outpatient treatment in this clinical trial setting).
Total CAP-related hospitalization costs for telithro­
mycin and clarithromycin patients were calculated in 
US dollars and com pared by treatment group. Overall 
costs o f  inpatient hospitalization were derived by 
multiplying the total number o f  CAP-related hospital 
days per treatment group by the average per diem cost 
rate for short-term hospitals in 2 0 0 0  (the year in which 
the clinical trial was perform ed), as published by the 
American Hospital Association (U S$1149 .40 )24.
Statistical Analysis
Healthcare resource utilization and hospitalization costs 
for each treatment group were compared. As two 
telithromycin treatments (5- and 7-day) were being 
com pared with one control (clarithromycin), analysis o f
variance applying the Dunnett adjustment25 was used to 
com pare continuous variables betw een  5-day 
telithromycin and clarithromycin and 7-day telithro­
mycin and clarithromycin, and to generate the 95% 
confidence intervals (CIs) for hospitalization costs. 
Fisher’s exact test was used for com parison o f  
categorical variables. Statistical analyses w ere 
perform ed at the 5% significance level. Statistical 




A  total o f  581 patients were enrolled in the study, o f  
whom  575 were randomized and received at least one 
dose o f study m edication (ITT population): 5-day 
telithromycin, n =  193; 7-day telithromycin, n =  195; 
10-day clarithromycin, n =  187. Six patients w ho were 
enrolled in the study were not randomized to treatment 
because o f  lack o f  chest X-ray findings consistent with 
bacterial CAP. There were no statistically significant 
differences across treatment groups in demographics, 
location o f treatment initiation (N o. o f  inpatients vs 
outpatients), or baseline clinical characteristics o f  the 
ITT populations (Table 1). The m odified ITT (m ITT) 
population (all ITT patients with clinical and radiologic 
confirmation o f  CAP) com prised 187 patients w ho 
received 5-day telithromycin, 191 patients w ho received 
7-day telithromycin, and 181 patients w ho received 
clarithromycin.
Clinical Efficacy and Safety
Clinical cure rates in the PPc populations at post­
therapy/TO C  were similar in the three treatment arms: 
89 .3%  (1 4 2 /1 5 9 ) for 5-day telithrom ycin, 8 8 .8 % 
(1 4 3 /1 6 1 ) for 7-day telithrom ycin, and 91.8%  
(1 3 4 /1 4 6 ) for 10-day clarithromycin. Both 5- and 7-day 
telithromycin were statistically equivalent to 1 0 -day 
clarithrom ycin (d ifference: -2 .5  and -3 .0 % , 
respectively; 95%  C l: -9 .7 ,  4 .7  and -1 0 .2 , 4 .3 , 
respectively). These results were supported by the 
analysis in the m ITT population, which also showed 
statistical equivalence -  154/187  (82.4% ) for 5-day 
telithromycin, 157/191 (82.2% ) for 7-day telithro­
m ycin, and 147 /181  (81 .2% ) for clarithrom ycin 
(d ifference: 1.1 and 1.0% for 5- and 7-day 
telithromycin, respectively; 95% C l: -7 .3 , 9.6 and -7 .4 , 
9.4, respectively). Statistical comparisons were not 
perform ed  betw een  5- and 7-day telithrom ycin.
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Table 1. Demographics and baseline clinical characteristics of the intent to treat population of patients who received 
telithromycin 800 mg once daily or clarithromycin 500 mg twice daily
Characteristic Treatment regimen
5-day telithromycin 
(»  =  193)
7-day telithromycin 
(»  =  195)
10-day clarithromycin 
(»  =  187)
Gender, n (%)
Male 121 (62.7) 103 (52.8) 97 (51.9)
Female 72 (37.3) 92 (47.2) 90 (48.1)
Age
Mean (range), years 45.8 (18 -87 ) 45.7 (19 -87 ) 46.0 (15 -88 )
Aged <  65 years, n (%) 161 (83.4) 165 (84.6) 148 (79.1)
Aged > 6 5  years, n (%) 32 (16.6) 30 (15.4) 39 (20.9)
Fine score, n (%)
Class I 94 (48.7) 97 (49.7) 89 (47.6)
Class II 62 (32.1) 63 (32.3) 58 (31.0)
Class III 23 (11.9) 21 (10.8) 29 (15.5)
Class IV 13 (6.7) 14 (7.2) 11 (5.9)
Class V 1 (0.5) 0 0
Initial location o f  treatment, n (%)
Outpatient 170 (88.1) 171 (87.7) 170 (90.9)
Inpatient 23 (11.9) 24 (12.3) 17 (9.1)
Table 2. Non-protocol driven healthcare resource utilization by patients who received telithromycin 800 mg once daily or
clarithromycin 500 mg twice daily (intent to treat populations)
Re source Treatment regimen Probability
5-day
telithromycin
(n =  193)
7-day 
telithromycin 
(n =  195)
10-day 
clarithromycin 






N o. o f patients 9 4 13 0.385 0.025
N o. o f events 9 4 13 0 .283 0.021
Adm issions/100 patients 4.7 2.1 7.0
CAP-related hospitalizations
N o. o f patients 3 1 7 0 .214 0.034
N o. o f events 3 1 7 0 .119 0.021
Adm issions/100 patients 1.6 0.5 3.7
CAP-related outpatient visits
N o. (%) o f patients 23 (11.9) 26 (13.3) 30 (16.0) 0 .300 0.473
No. o f observations (observations/100 patients) 74 (38.3) 62 (31.8) 92 (49.2) 0 .474 0 .250
CAP-related laboratory tests
N o. (%) o f patients 26 (13.5) 27 (13.8) 26 (13.9) 1 .000 1.000
No. o f observations (observations/100 patients) 139 (72.0) 127 (65.1) 185 (98.9) 0 .490 0.385
RTI-related additional antibacterial agents
N o. (%) o f patients 27 (14.0) 26 (13.0) 34 (18.0) 0 .328 0.208
No. o f observations (observations/100 patients) 46  (23.8) 32 (16.4) 54 (28.9) 0 .492 0.089
Duration o f IV antibacterial therapy (days) 79 56 119 0 .434 0.223
Duration o f oral antibacterial therapy (days) 256 169 241 0.921 0.257
Analysis o f variance was used to compare continuous variables and Fisher’s exact test was used to compare categorical variables. 
CAP, community-acquired pneumonia; IV, intravenous; RTI, respiratory tract infection.
Bacteriologic outcom e rates for telithrom ycin and 
clarithromycin were similar (bacteriologically evaluable 
per-protoco l population) and the tw o agents had 
comparable tolerability profiles.
Health O utcom es and Healthcare 
Resource Utilization
As there were no significant differences in clinical 
efficacy betw een telithromycin (5- and 7-day) and 10- 
day clarithromycin, cost minimization analyses were 
perform ed. As treatm ent failure -  particularly
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hospitalization -  is the major driver o f  healthcare 
resource utilization in CAP, the cost comparison analysis 
focused on non-protocol-related healthcare resource 
utilization due to hospitalization.
Hospitalizations and Associated Costs
There were 13 hospital admissions (all causes) in the 
clarithromycin group vs 9 (p  =  0 .283) in the 5-day 
telithromycin group and 4 (p  =  0 .021) in the 7-day 
telithrom ycin  group (Table 2 ). O f  the total 
hospitalizations, 7 were considered CAP-related in the
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Table 3. Community-acquired pneumonia-related hospitalization listings for patients who received telithromycin 800 mg once 











5-day telithromycin Brazil 20/M 1 4 13 Pleural effusion, worsening
Germany 44/M 3 22 1 Relapse o f pneumonia
Germany 57/M 2 25 19 Pneumonia
7 -day telithromycin South Africa 39/M 3 24 14 Severe pneumonia, septic shock
10-day clarithromycin USA 71/F 2 2 11 Pneumonia
South Africa 64/F 4 2 7 Increased chest pain and bronchospasm
USA 51/F 2 3 2 Possible sepsis
Canada 51/F 2 6 9 Pneumonia aggravation; treatment failure
USA 57/M 3 7 9 Worsening symptoms of pneumonia
Canada 37/M 2 26 16 Increased shortness o f breath
Germany 69/M 3 33 21 Proteinuria
F, female; M, male.
Table 4. Community-acquired pneumonia-related hospitalization data for patients treated with telithromycin 800 mg once daily vs
clarithromycin 500 mg twice daily (intent to treat populations)
Patient subset Treatment regimen
5-day telithromycin 
(n =  193)
7-day telithromycin 
(n =  195)
10-day clarithromycin 
(n =  187)
No. o f  hospitalizations 3 1 7
Probability vs clarithromycin 0.119 0.021 -
Admissions/100 patients 1.6 0.5 3.7
ICU admissions; No. o f  patients (No. o f
observations) 0 1 (1) 0
Total length o f hospital stay (range), days 33 (1 -1 9 ) 14 (14 -14 ) 75 (2 -2 1 )
Hospital days/100 patients 17.1 7.2 40.1
Probability vs clarithromycin 0.197 0.064 -
Total hospitalization costs $37 930.20 $16091.60 $86205.00
Hospitalization costs per 100 patients $19653 $8252 $46099
Probability vs clarithromycin 0.197 0.197 -
Difference vs clarithromycin per 100 patients -$ 2 6  446 -$ 3 7  847 -
95% C l -6 6  654; 13 762 -7 7  953; 2259 -
Analysis of variance was used to compare treatments and to generate the 95%  CIs for hospitalization costs. 
C l, confidence interval; IC U , intensive care unit.
clarithromycin group vs 3 (p  =  0 .119 ) among 5-day 
telithromycin recipients and 1 (p  =  0 .021) among 7-day 
telithromycin recipients. This equated to a CAP-related 
hospitalization rate o f  3.7 hospitalizations per 100 
patients treated with clarithromycin vs 1.6 and 0.5 
hospitalizations per 100 patients receiving 5- and 7-day 
telithromycin, respectively (1 .0  per 100 patients for 5- 
and 7-day com bined; p =  0 .026 ). Information regarding 
patients hospitalized for C AP-related reasons is 
presented in Table 3; treatment was initiated in the 
outpatient setting for all patients listed. The mean 
(median) length o f  CAP-related hospital stay was 11 
(9) days for clarithromycin patients vs 14 (14) days for 
5-day and 11 (1 3 ) days for 7-day telithrom ycin  
patients. The total number o f  CAP-related hospital 
days (all patients hospitalized for CAP-related reasons) 
was 40.1 days per 100 patients for clarithromycin vs
17.1 (p  =  0 .197) and 7.2 (p  =  0 .064) days per 100 
patients for 5- and 7-day telithromycin, respectively 
(Table 4) (12.1 days per 100 patients for 5- and 7-day 
telithromycin com bined; p =  0 .07).
Similar rates o f hospitalization were observed in the 
mITT population o f  patients, with 3.9, 1.6, and 0.52 
hospitalizations per 1 0 0  patients receiving clarithro­
mycin, 5-day telithromycin, and 7-day telithromycin, 
respectively (1.1 days per 100 patients for 5- and 7-day 
telithromycin com bined; data not shown). The total 
number o f  CAP-related hospital days was 41.4  days per 
100 patients for clarithromycin vs 17.6 and 7.3 days per 
100 patients for 5 - and 7-day telithrom ycin, 
respectively, (1 2 .4 days per 100 patients for 5- and 7- 
day telithromycin com bined).
Projected overall CAP-related hospitalization costs 
per 100 patients were $ 8 6  205 for clarithromycin vs
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$ 3 7930  (difference: -2 6 4 4 6 ; 95% Cl: -6 6 6 5 4 ; 13 762) 
and $16 091 (difference: -3 7  847; 95% C l: -7 7  953; 
2259) for 5- and 7-day telithromycin, respectively 
(Table 4 ). The difference in hospitalization costs did not 
achieve statistical significance due to the small effect 
size (very few  patients hospitalized) and/or the large 
variance in cost.
O ther Healthcare Resource Utilization
A  summary o f  non-protocol driven resource utilization 
by patients who received telithromycin 800 mg once 
daily or clarithromycin 500 mg tw ice daily is presented 
in Table 2. The number o f  CAP-related unscheduled 
outpatient visits and laboratory tests for patients re­
ceiving telithromycin and clarithromycin were similar. A  
similar proportion o f  telithromycin and clarithromycin 
recipients required additional RTI-related antibacterial 
therapy (Table 2). The total duration o f  intravenous 
antibacterial treatm ent for clarithrom ycin-treated 
patients was 119 days (63 .6  days per 100 patients) 
com pared with 79 days (40 .9  days per 100 patients) for 
5-day telithromycin and 56 days (28.7  days per 100 
patients) for 7-day telithrom ycin. In the m ITT 
population, the duration o f  intravenous antibacterial 
treatm ent for clarithrom ycin-treated patients was
65.2 days per 100 patients com pared with 38.5 and
28 .8  days per 100 patients for  5- and 7-day 
telithromycin, respectively.
Discussion
Antibacterial prescribing for CAP is influenced by a 
number o f  issues, such as patient compliance, drug 
adverse-event profiles, and the local prevalence o f 
resistance4,26. Combination therapy with a macrolide and 
a P-lactam with good  antipneum ococcal activity is 
generally recom m ended  for  the treatm ent o f  
outpatients with risk factors for drug-resistant S. 
pneumoniae6,13,14. M onotherapy with a fluoroquinolone is 
a possible alternative, although controversy as to the 
suitability o f  fluoroquinolones for first-line therapy 
exists in current guidelines61314. Antibacterial resistance 
may therefore  play a role in increasing overall 
management costs through 'preventative use’ o f  
com bination therapy, treatm ent o f  relapses, and 
hospitalizations. W ith increasing levels o f  antibacterial 
resistance among S. pneumoniae16 27, empiric selection o f 
an effective  drug may becom e m ore challenging. 
Telithromycin provides coverage against the com m on 
causative agents o f  CAP -  including atypical/intra­
cellular pathogens and strains o f  S. pneumoniae that are 
resistant to currently available agents -  and the clinical
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efficacy o f  telithromycin in CAP has been demonstrated 
in several studies17-21.
The clinical data from  the present randomized, 
double-b lind  study show ed that the e fficacy  o f  
telithromycin 800 mg once daily for 5 or 7 days and 
clarithromycin tw ice daily for 1 0  days in the treatment 
o f  patients with CAP was statistically equivalent. The 
data from  the present patient outcom e and hospital­
ization cost analyses show ed that, com pared with 
clarithromycin treatment, 5-day telithromycin treat­
ment was associated with a trend towards numerically 
few er hospitalizations and days required in hospital, and 
7-day telithrom ycin treatment was associated with 
significantly few er hospitalizations and a trend towards 
few er days required in hospital. Projected CAP-related 
hospitalization costs were therefore num erically 
reduced for 5- and 7-day telithromycin recipients vs 
clarithromycin recipients. A  comparison o f  indirect 
costs -  such as days o f  reduced productivity and work 
loss -  were beyond the scope o f  this analysis.
The direct healthcare resource utilization findings 
from  this study are consistent with data from  three 
separate studies involving patients with C AP (one 
study) and acute exacerbations o f  chronic bronchitis 
(AECB; tw o studies), respectively. Treatment with 
telithromycin 800 mg once daily for 5 (AECB studies) 
or 10 (CAP study) days was associated with a trend 
towards few er hospitalizations and/or hospital days than 
treatment with clarithromycin 500 mg tw ice daily or 
amoxicillin-clavulanate 500 /125  mg three-times daily 
for 1 0  days22,28,29.
The present study was pow ered to  demonstrate 
equivalence in clinical efficacy betw een treatments. 
However, the results suggest that antibacterial agents 
with similar clinical efficacies may potentially be 
associated with differences in the overall costs o f  
treatment owing to differences in additional healthcare 
resources consum ed during the course o f  care. This is 
due, in part, to  the fact that several o f  the components 
associated with treatment failure, particularly hospital­
ization, are very expensive. C ost savings result from  
prevention o f  disease progression to the point where 
inpatient care is necessary or from  reduction in length o f 
stay in hospital.
The reasons for the lower rate o f  hospitalization 
among 7-day telithrom ycin recipients are currently 
unclear, given that clinical cure rates were equivalent to 
those o f  clarithromycin. A  possible explanation is the 
favorable pharmacokinetic/pharmacodynamic profile o f  
telithromycin for the treatment o f  RTIs. Telithromycin 
achieves a high area under the serum concentration-time 
curve to minimum inhibitory concentration ratios for key 
respiratory pathogens and maintains high concentrations 
in respiratory tissues and fluids30. Telithromycin also 
exhibits rapid bactericidal activity against S. pneumoniae,
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the most frequent causative pathogen in C AP1". Such a 
profile may lead to a faster resolution o f  infection and 
more rapid symptom relief1'2, although further studies 
would be required to support this theory.
This study had a number o f  limitations. The clinical 
trial was designed to demonstrate equivalence in clinical 
efficacy  and was not statistically pow ered to 
dem onstrate d ifferences in healthcare resource 
utilization -  there were very few  patients hospitalized in 
either treatment group and there was a large variance in 
projected hospitalization costs. In addition, CAP-related 
hospitalizations w ere assessed in this study by 
investigators w ho were blinded to treatment group at 
the time o f  admission, in order to provide an unbiased 
reflection o f  CAP-related hospitalization rates for each 
treatment. Nevertheless, this approach could still be 
considered as somewhat subjective. Although this was a 
multinational study, the analysis was perform ed from  a 
US managed care perspective and results o f  the 
hospitalization cost analyses are reported in US dollars. 
Hospitalization cost data presented here may not be 
directly applicable to other countries due to differences 
in reference prices, although this is unlikely to 
substantially affect the overall data trends observed. 
Furtherm ore, criteria for hospital admission (e.g. 
patients in some countries may be admitted for social 
rather than clinical reasons) and length o f  stay may also 
vary by country, potentially contributing to differences 
in treatment costs. Given that patients were random­
ized at the center level and given the overall spread o f 
countries involved in the hospitalization analyses, 
international practice differences are also unlikely to 
substantially affect the overall data trends observed.
Because o f  the limitations o f  the study, the data from 
these patient outcom e and cost analyses should be 
regarded as observational. That similar trends in 
requirement for hospitalizations/hospital days -  trans­
lating into differences in consumption o f  healthcare 
resources -  between patients receiving telithromycin and 
clarithromycin were observed in tw o other separate 
studies22'2-', however, adds support to the findings o f  the 
present study. Furthermore, statistically significant 
differences in CAP-related hospitalization rates were 
observed for 7-day telithromycin vs clarithromycin in the 
present study, despite the fact that the clinical trial was 
designed to demonstrate equivalence in clinical efficacy 
and was not statistically pow ered to demonstrate 
differences in healthcare resource utilization.
In summary, previous studies have demonstrated that 
telithromycin 800 mg once daily for 5 -1 0  days is an 
effective therapy for adolescent and adult outpatients 
with CAP o f  mild to moderate severity1 ~21. Data from  
this patient outcom es analysis suggest that 
telithromycin 800 mg once daily for 7 days for the 
management o f  CAP is associated with significantly
few er hospitalizations and numerically few er hospital 
days than clarithromycin 500m g twice daily for lOdays, 
resulting in potentially lower projected hospitalization 
costs. That significant differences in hospitalization rates 
were observed for 7-day telithromycin vs clarithromycin 
is o f  interest, as the most likely dosing regimen for 
telithromycin in the treatment o f  CAP is 800 mg once 
daily for 7 -1 0  days. Given the prevalence o f  CAP, 
potential reductions in additional direct healthcare 
resource consumption may have important implications 
for reducing annual treatment costs. Further studies to 
add support to the findings o f  these preliminary analyses 
are therefore warranted.
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